EICHOR
● Terminated
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Condition: Cervical Cancer · Sponsor: Seagen, a wholly owned subsidiary of Pfizer
About this study
This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (71)
| Arizona Oncology Associates | Phoenix, Arizona, United States | — |
| Univ California, Irvine Medical Center | Orange, California, United States | — |
| Olive View - UCLA Research and Education Institute | Sylmar, California, United States | — |
| Baptist MD Anderson Cancer Center | Jacksonville, Florida, United States | — |
| Augusta University | Augusta, Georgia, United States | — |
| University of Chicago | Chicago, Illinois, United States | — |
| Indiana University School of Medicine | Indianapolis, Indiana, United States | — |
| University of Kansas Medical Center | Westwood, Kansas, United States | — |
| Oschner Clinic | New Orleans, Louisiana, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| Billings Clinic Cancer Center | Billings, Montana, United States | — |
| Montana Cancer Consortium | Billings, Montana, United States | — |
+ 59 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03786081